nL-CHCHD-001

DRUG4 trials

Sponsors

n-Lorem Foundation

Conditions

Amyotrophic Lateral Sclerosis

Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Active, not recruitingNCT06392126

n-Lorem FoundationAmyotrophic Lateral Sclerosis

Start: 2024-04-16End: 2027-04-01Updated: 2026-07-13

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

Active, not recruitingNCT06977451

n-Lorem FoundationAmyotrophic Lateral Sclerosis

Start: 2024-06-24End: 2027-06-01Updated: 2026-07-13

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

Enrolling by invitationNCT07095686

n-Lorem FoundationAmyotrophic Lateral Sclerosis

Start: 2024-10-02End: 2027-04-01Target: 9Updated: 2026-07-13

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

Not yet recruitingNCT07423494

n-Lorem FoundationAmyotrophic Lateral Sclerosis

Start: 2026-03-01End: 2027-03-01Target: 1Updated: 2026-02-20

Related Papers

N-of-1 investigational study of a novel antisense oligonucleotide drug in CHCHD10-related ALS shows early signs of efficacy.

2026-09-14